Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Other Operating Expenses: 2021-2025

Historic Other Operating Expenses for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to $110,196.

  • InMed Pharmaceuticals' Other Operating Expenses rose 408.21% to $110,196 in Q3 2025 from the same period last year, while for Sep 2025 it was $279,619, marking a year-over-year increase of 579.68%. This contributed to the annual value of $191,106 for FY2025, which is 166.99% up from last year.
  • Per InMed Pharmaceuticals' latest filing, its Other Operating Expenses stood at $110,196 for Q3 2025, which was up 498.60% from $18,409 recorded in Q2 2025.
  • InMed Pharmaceuticals' Other Operating Expenses' 5-year high stood at $145,839 during Q3 2022, with a 5-year trough of -$8.8 million in Q2 2022.
  • For the 3-year period, InMed Pharmaceuticals' Other Operating Expenses averaged around $46,835, with its median value being $62,268 (2025).
  • Within the past 5 years, the most significant YoY rise in InMed Pharmaceuticals' Other Operating Expenses was 448.39% (2024), while the steepest drop was 133.60% (2024).
  • Quarterly analysis of 5 years shows InMed Pharmaceuticals' Other Operating Expenses stood at -$2.9 million in 2021, then spiked by 98.46% to -$44,315 in 2022, then skyrocketed by 34.47% to -$29,040 in 2023, then spiked by 405.60% to $88,746 in 2024, then spiked by 408.21% to $110,196 in 2025.
  • Its Other Operating Expenses was $110,196 in Q3 2025, compared to $18,409 in Q2 2025 and $62,268 in Q1 2025.